Why Is Novo Nordisk Stock Climbing Premarket Today?

• The Wegovy pill generated $351 million in first-quarter sales and topped 2 million prescriptions since its January U.S. launch.
• Novo sees significant opportunity in the UAE, where 28% of adults are living with obesity.
• Novo faces growing competition from Eli Lilly's oral obesity drug, Foundayo, and uncertainty over U.S. drug-pricing policies.

Shares of Novo Nordisk (NVO) rose 0.3% in premarket trading on Wednesday after the drugmaker launched its Wegovy pill in the United Arab Emirates (UAE), making the blockbuster obesity treatment available outside the U.S. for the first time.

NVO stock slipped nearly 3% on Tuesday, recording its second straight session of losses. 

Wegovy Pill Launches In UAE

Novo Nordisk said the UAE has become the first country outside the U.S. to launch the Wegovy pill, marking the start of the company's international rollout of the oral obesity treatment. The company said that additional launches are planned in select markets during the second half of this year. 

“As we look to future launches, our approach will be guided by local patient demand, the readiness of healthcare professionals, and the strength of healthcare and telehealth infrastructure that can support long-term obesity care,” Emil Kongshoj Larsen, executive vice president of international operations, said in a statement. 

The company said that the UAE is a significant market opportunity for Novo, with 28% of adults in the country living with obesity, while nearly 7.5 million people are projected to be living with obesity or overweight by 2035.

Wegovy Pill Offers Injection-Like Weight Loss

Wegovy pill is the first daily weight-loss pill in the GLP-1 drug class approved for long-term weight management approved by both U.S. and UAE regulators to help lower the risk of serious heart-related events, including heart attacks and strokes.

The approval was based on Novo Nordisk's Oasis 4 clinical trial. In the study, people taking the Wegovy pill once a day lost an average of 17% of their body weight. Novo said the results were similar to those seen with injectable Wegovy, with about one-third of participants losing 20% or more of their body weight. The company added that the pill's safety profile was consistent with earlier studies of Semaglutide-based treatments.

Strong US Wegovy Debut Fuels Global Push

The international launch comes after a strong commercial debut for the product in the U.S. Novo reported first-quarter (Q1) Wegovy pill sales of 2.26 billion Danish crowns ($351 million), nearly double analyst expectations. The company also said that prescriptions hit 1.3 million in Q1 and over 2 million since the pill's January launch, making it the largest GLP-1 launch by volume in the U.S. market.

Last month, CEO Mike Doustdar said that Novo remained committed to launching the Wegovy pill internationally during the second half of this year despite concerns that proposed U.S. "most-favored-nation" drug-pricing policies could affect overseas launches. Novo has also submitted the pill for review by the European Medicines Agency (ENA) and other regulators.

The launch comes as competition in the obesity market continues to intensify following the recent launch of Eli Lilly's oral weight-loss drug, Foundayo. However, Novo said that demand for obesity treatments remains strong and that lower prices are helping expand patient access, while driving higher prescription volumes. 

Novo Bets On AI To Speed Drug Launches

Novo is also pushing the use of AI across its operations to shorten the time required to bring new medicines to market. Last week, John Dawber, managing director of global business services, said that the company is deploying AI across regulatory documentation, safety analysis and commercial planning. 

Meanwhile, Novo's obesity franchise continues to drive Denmark's broader economy. Recently, Danske Bank raised its 2026 Danish GDP growth forecast to 3.7%, citing strong export demand driven in part by Novo Nordisk products. Chief economist Las Olsen said that export volumes continue to rise as demand for the company's medicines remains strong, according to Bloomberg.

How Do Retail Traders Feel About NVO?

On Stocktwits, retail sentiment for Novo was ‘bearish’ amid ‘low’ message volume.

One user said, “Nvo future drugs sound like they're going to top LLY or match it to even the playing field there and lilly’s oral flopdayo is well flopping bigly.”

Another user said, “$NVO highly considering tax loss harvesting this pos. Just don’t see this stock ripping in the near future. I get it’s undervalued but this is an irrational market. Even when sector shifts happen into pharma or healthcare, this never catches a bid. UNH, HUM, LLY all run and this one. Nah.”

NVO stock has declined 39% over the past year. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: GRRR Stock Slides Premarket Despite A $2B AI Deal With Supermicro — Here's Why